As reported on BioSpace, Moderna has entered a commercialization partnership with Italy‑based Recordati to support the development of mRNA‑3927, an investigational mRNA therapy for propionic acidemia (PA). The agreement, announced Friday, includes a $50 million upfront payment to Moderna and up to $110 million in additional development and regulatory milestones, along with future royalties.
A New Approach to a Devastating Metabolic Disease
Propionic acidemia is an inherited metabolic disorder in which patients lack key enzymes needed to break down certain amino acids and fats. The resulting buildup of toxic acids can trigger acute, potentially fatal metabolic crises. Symptoms typically emerge soon after birth and may include feeding difficulties, poor muscle tone, and recurrent vomiting. Severe decompensation can lead to seizures, coma, or death.
Moderna’s therapeutic candidate, mRNA‑3927, is designed to deliver genetic instructions that enable the body to produce the two enzymes missing in people with PA. Early clinical data suggest that this strategy may reduce the incidence of metabolic crises.
Clinical Progress to Date
In a Phase I/II study published in Nature in 2024, mRNA‑3927 demonstrated a 70% reduction in metabolic decompensation events among eight treated patients over a year. While nearly all participants experienced treatment‑related adverse events—most commonly mild to moderate—Moderna reported that serious safety concerns requiring discontinuation were uncommon. The company has signaled that pivotal results are expected later this year, which could be critical for regulatory planning.
Role Division Under the New Deal
Under the collaboration:
- Moderna will continue to oversee clinical development, regulatory activities, and manufacturing of mRNA‑3927.
- Recordati, which has a global footprint in rare disease commercialization, will take the lead on marketing and distribution if the therapy receives approval.
Financial and Strategic Context
The deal arrives during a challenging period for Moderna. As demand for COVID‑19 vaccines has waned, the company has been pursuing cost‑reduction strategies to meet its goal of breaking even by 2028. Despite reporting fourth‑quarter revenues at the higher end of projections, analysts have said that further financial discipline may be necessary. The Recordati partnership gives Moderna a commercialization ally while allowing it to focus resources on clinical advancement of its rare disease pipeline.
